Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms

Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of antidiabetic medications that cause glucose-dependent increase in incretins in diabetic patients. One of the two incretins, glucagon-like peptide-1 (GLP-1), beside its insulinotropic activity, has been studied for extra pancreatic effects. Most...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakaria, Esraa M., Tawfeek, Walaa M., Hassanin, Mohamed H., Hassaballah, Mohammed Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568460/
https://www.ncbi.nlm.nih.gov/pubmed/35945358
http://dx.doi.org/10.1007/s00210-022-02279-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568460/
https://www.ncbi.nlm.nih.gov/pubmed/35945358
http://dx.doi.org/10.1007/s00210-022-02279-3

Ejemplares similares